Ocugen Falls as Eye Gene Therapy Lags in Phase II
Ocugen Stock Drops After Eye Disease Gene Therapy Trial Disappoints The world of biotechnology is a high-stakes arena, where a single clinical trial result can send a company’s valuation soaring or plummeting. This volatile reality hit home for Ocugen, Inc. (NASDAQ: OCGN) this week, as the company’s shares experienced a sharp decline following the release […]
Ocugen Falls as Eye Gene Therapy Lags in Phase II Read More »
